- Dr. Jane F. Barlow Appointed as Independent Director -
BOCA RATON, Fla.--(BUSINESS WIRE)--Apr. 2, 2018--
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare
company, today announced the appointment of Jane F. Barlow, M.D.,
M.B.A., M.P.H. as an independent director to the Board of Directors.
Dr. Barlow previously served as Associate Chief Medical Officer for CVS
Health and Chief Medical Officer of CVS Health’s Medicare and Government
Services business segment, where she drove clinical strategies
supporting drug purchasing, distribution, and utilization management for
over five billion annual prescriptions. Prior to CVS Health, she served
as Vice President of Clinical Innovation at MEDCO Health Solutions,
focused on clinical innovations into all aspects of pharmacy and
pharmacy benefits management for over 60 million members. Dr. Barlow is
currently the Chief Executive Officer of Jane Barlow & Associates, LLC.
Dr. Barlow is a clinical and strategic executive with over 25 years of
leadership experience in driving cost-effective medical, diagnostic, and
pharmaceutical strategies, directing corporate health benefits,
delivering patient care, and supporting health systems. She is a
recognized leader in payer reimbursement, health policy, technology,
quality and compliance, benefits design, and population health
management. Dr. Barlow is active in evaluating the economic impact and
value of pharmaceuticals and diagnostics to aid payers and manufacturers
in defining access and coverage strategies.
“We are very pleased to add Dr. Barlow as the newest independent
director to our Board. She has a wealth of experience as both a director
and a member of senior management at successful healthcare
organizations,” said TherapeuticsMD CEO Robert G. Finizio. “This is an
exciting time in our company’s growth and development, and Dr. Barlow’s
skill set complements our transformation to a commercial organization in
the years ahead.”
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative healthcare company focused on
developing and commercializing products exclusively for women. With its
SYMBODA™ technology, TherapeuticsMD is developing advanced hormone
therapy pharmaceutical products to enable delivery of bio-identical
hormones through a variety of dosage forms and administration routes.
The Company’s late stage clinical pipeline includes two product
candidates that have completed phase 3 trials and are awaiting approval
by the FDA: TX-001HR for treatment of moderate-to-severe vasomotor
symptoms (VMS) due to menopause and TX-004HR for treatment of
moderate-to-severe vaginal pain during sexual intercourse (dyspareunia),
a symptom of vulvar and vaginal atrophy (VVA) due to menopause. The
Company also manufactures and distributes branded and generic
prescription prenatal vitamins under the vitaMedMD® and BocaGreenMD®
brands.
Forward-Looking Statements
This press release by TherapeuticsMD, Inc. may contain
forward-looking statements. Forward-looking statements may include, but
are not limited to, statements relating to TherapeuticsMD’s objectives,
plans and strategies as well as statements, other than historical facts,
that address activities, events or developments that the company
intends, expects, projects, believes or anticipates will or may occur in
the future. These statements are often characterized by terminology such
as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,”
“plans,” “will,” “expects,” “estimates,” “projects,” “positioned,”
“strategy” and similar expressions and are based on assumptions and
assessments made in light of management’s experience and perception of
historical trends, current conditions, expected future developments and
other factors believed to be appropriate. Forward-looking statements in
this press release are made as of the date of this press release, and
the company undertakes no duty to update or revise any such statements,
whether as a result of new information, future events or otherwise.
Forward-looking statements are not guarantees of future performance and
are subject to risks and uncertainties, many of which are outside of the
company’s control. Important factors that could cause actual results,
developments and business decisions to differ materially from
forward-looking statements are described in the sections titled “Risk
Factors” in the company’s filings with the Securities and Exchange
Commission, including its most recent Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and
include the following: the company’s ability to resolve the deficiencies
identified by the FDA in the company’s new drug application for its
TX-004HR product candidate and the time frame associated with such
resolution; whether the FDA will approve the amended NDA for the
company’s TX-004HR product candidate and whether such approval will
occur by the PDUFA target action date; whether the FDA will approve the
NDA for the company’s TX-001HR product candidate and whether such
approval will occur by the PDUFA target action date; the company’s
ability to maintain or increase sales of its products; the company’s
ability to develop and commercialize its hormone therapy drug candidates
and obtain additional financing necessary therefor; the length, cost and
uncertain results of the company’s clinical trials, including any
additional clinical trials that the FDA may require in connection with
TX-004HR; the potential of adverse side effects or other safety risks
that could preclude the approval of the company’s hormone therapy drug
candidates; the company’s reliance on third parties to conduct its
clinical trials, research and development and manufacturing; the
availability of reimbursement from government authorities and health
insurance companies for the company’s products; the impact of product
liability lawsuits; the influence of extensive and costly government
regulation; the volatility of the trading price of the company’s common
stock and the concentration of power in its stock ownership. PDF copies
of the company’s historical press releases and financial tables can be
viewed and downloaded at its website: www.therapeuticsmd.com/pressreleases.aspx.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180402005091/en/
Source: TherapeuticsMD, Inc.
TherapeuticsMD, Inc.
David DeLucia, 561-961-1900
Director,
Investor Relations
David.DeLucia@TherapeuticsMD.com
